
Rain Therapeutics Investor Relations Material
Latest events

Q2 2023
Rain Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Rain Therapeutics Inc
Access all reports
Rain Oncology Inc. (formerly Rain Therapeutics Inc.) is a biotechnology company focused on developing precision oncology therapies. It targets oncogenic drivers to select patients based on the genetic profile of their tumors. The company's lead product candidate, milademetan, is an oral small-molecule inhibitor designed to block the MDM2-p53 interaction, a key pathway in many cancers. Rain Oncology is also advancing preclinical programs, including a RAD52 inhibitor aimed at exploiting synthetic lethality in certain cancer types with homologous recombination deficiencies. The company is headquartered in Newark, California, and its shares trade on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
RAIN
Country
🇺🇸 United States